Lentivirus Protocol
This guide explains the lentivirus protocol for researchers and lab technicians who need a practical, source bounded framework for producing and using lentiviral vectors. Lentivirus protocols are essential for stable gene delivery into dividing and nondividing cells, with applications from basic research to cell therapy NCBI Bookshelf. Use this guide to understand the core steps, make informed decisions, and avoid common pitfalls. Lentiviral vectors derived from HIV 1 offer high transduction efficiency and sustained expression, making them a workhorse in modern molecular biology Bridging preclinical development and clinical manufacturing.
At a Glance
| Aspect | Detail |
|---|---|
| Purpose | Deliver genetic material stably into mammalian cells |
| Vector backbone | Self inactivating (SIN) lentiviral plasmid |
| Packaging system | Three or four plasmid system (second or third generation) |
| Producer cells | HEK 293T or HEK 293FT |
| Safety level | BSL 2 with enhanced practices (BSL 2+) |
| Harvest method | Ultracentrifugation or PEG precipitation |
| Typical titer | 10^6 to 10^8 transduction units per mL |
| Key quality check | Functional titer assay on target cells |
Core Concepts
Lentiviruses are a genus of retroviruses that can infect both dividing and quiescent cells. The standard research protocol uses replication defective lentiviral particles produced by transient transfection EMBL EBI Training. The system separates the viral genome into multiple plasmids to prevent replication competent lentivirus (RCL). The transfer plasmid contains the gene of interest flanked by long terminal repeats (LTRs). Packaging plasmids supply gag, pol, rev, and often a heterologous envelope glycoprotein (commonly VSV G) Overexpression of Chimeric RNA by Retroviral Transduction. The envelope plasmid determines viral tropism. After transfection into packaging cells, viral particles bud from the cell membrane and are harvested from culture supernatant.
Vector generations
Second generation packaging systems combine gag pol and rev on one plasmid, with the envelope on a separate plasmid. Third generation systems split gag pol and rev onto distinct plasmids, reducing recombination risk. Third generation also uses a Rev independent transfer plasmid. Choose second generation for simpler workflows or third generation for increased safety in translational work Galaxy Training Network.
Decision Criteria
Selecting the right components for your lentivirus protocol depends on your experimental goals.
Packaging system choice. Use second generation (three plasmids) for routine overexpression or knockdown in immortalized cell lines. Use third generation (four plasmids) when preparing vectors for primary cells or in vivo studies where RCL risk must be minimized.
Envelope selection. VSV G is the standard for broad tropism and particle stability during concentration. Replace with a pseudotype envelope (e.g., RD114, Baboon retrovirus) when targeting specific cell types or minimizing immune detection.
Promoter choice. Strong constitutive promoters (EF1 alpha, CMV) work in most lines. Cell specific promoters reduce off target expression. Use inducible systems (TRE, Tet On) for toxic genes.
Transfection method. Calcium phosphate is cost effective but variable. Polyethylenimine (PEI) offers consistency. Lipid based methods (Lipofectamine 3000) yield higher titers for small scale production Bioconductor. For clinical grade work, adhere to GMP compliant reagents and protocols Bridging preclinical development and clinical manufacturing.
Practical Workflow
This workflow covers production of lentiviral particles from plasmid transfection to transduction of target cells.
1. Seed packaging cells
Plate HEK 293T cells at 60 to 70 percent confluence in DMEM with 10 percent FBS. Use a 10 cm dish for pilot studies or T175 flask for larger batches. Culture for 18 to 24 hours until cells reach 80 to 90 percent confluence.
2. Prepare transfection mix
For a 10 cm dish, combine 10 micrograms of transfer plasmid, 5 micrograms of gag pol plasmid (e.g., psPAX2), 3 micrograms of envelope plasmid (e.g., pMD2.G), and 2 micrograms of rev plasmid if using third generation. Add to 500 microliters of serum free medium. Mix with 60 microliters of PEI (1 mg per mL) or calcium phosphate reagents according to your protocol.
3. Transfect cells
Replace culture medium with 10 mL of fresh DMEM with 2 percent FBS. Add transfection mix dropwise to the dish. Swirl gently. Incubate for 8 to 16 hours. Replace with fresh medium containing 2 percent FBS.
4. Harvest virus
Collect supernatant 48 and 72 hours post transfection. Filter through 0.45 micron PVDF filter to remove cellular debris. Pool the harvests. Optionally add PEG 8000 to 8 percent final concentration and incubate at 4 degrees Celsius for 4 hours or overnight. Centrifuge at 1500 x g for 45 minutes. Resuspend pellet in a small volume of serum free medium or PBS.
5. Concentrate particles
For higher titers, ultracentrifuge at 50,000 x g for 90 minutes at 4 degrees Celsius. Resuspend pellet in 1/100 of the original volume. Aliquot and snap freeze on dry ice. Store at minus 80 degrees Celsius.
6. Titer the virus
Use a functional assay on target cells. Transduce serial dilutions of stock on HEK 293T cells. After 72 hours, measure reporter expression (GFP, RFP) by flow cytometry or selectively count colonies under antibiotic selection. Calculate transduction units per mL.
7. Transduce target cells
Plate cells at 50 to 70 percent confluence. Add virus at a multiplicity of infection (MOI) of 1 to 10 in medium containing 8 micrograms per mL polybrene. Centrifuge at 1200 x g for 30 minutes at 30 degrees Celsius (spinoculation). Incubate for 24 hours. Replace with fresh medium. Analyze after 72 hours for transient expression or after 7 days for stable integration.
Quality Checks
Monitor critical quality attributes to ensure reproducible results NCBI Sequence Read Archive. Quality checks apply to both research and preclinical preparations.
Physical titer. Measure p24 capsid protein by ELISA. A p24 concentration of 100 ng per mL roughly equals 10^8 viral particles per mL. This does not measure infectivity.
Functional titer. As described in step 6. This is the most relevant metric for experiments.
Purity check. Run a blue staining method to evaluate residual transfection reagent or cellular protein. For clinical use, test for host cell DNA and protein contaminants per regulatory guidelines Bridging preclinical development and clinical manufacturing.
Sterility. Test for bacterial and fungal contamination by plating on LB agar or using a commercial sterility test. Mycoplasma detection is critical for any cell based work.
Replication competent lentivirus. Amplify vector on permissive cells for 3 passages and assay for p24 or by PCR for gag sequences. RCL must be absent for in vivo applications.
Common Mistakes
Low titer. This usually arises from suboptimal cell density at transfection, poor DNA quality, or using cells beyond passage 15. Always use low passage HEK 293T cells and measure DNA concentration accurately EMBL EBI Training.
Toxicity from transfection reagent. Calcium phosphate and PEI can be toxic if incubation times are too long or if precipitate is too coarse. Limit exposure to 8 hours for calcium phosphate.
Degradation of viral particles. Freeze thaw cycles reduce infectivity. Aliquot stocks and thaw once. Store at minus 80 degrees Celsius without repeated freeze thaw.
Carryover of plasmid DNA. Residual transfer plasmid in the viral stock can transfect target cells and give false positive signals. Treat stocks with DNase I before titering.
Overestimating MOI. Titer on the exact target cell type used in the experiment. Titer on HEK 293T does not predict transduction efficiency in primary cells Interleukin 38 promotes alveolar bone repair in periodontitis.
Limits and Uncertainty
Lentiviral vectors integrate randomly into the host genome, raising concerns about insertional mutagenesis. This risk is lower than with gamma retroviruses but nonzero. Self inactivating LTRs reduce the chance of activating nearby oncogenes.
Expression can be silenced by epigenetic modifications, especially in stem cells. Use promoters resistant to silencing, such as EF1 alpha or PGK, when working with pluripotent cells.
The protocol described here is for research use only. Translating a research grade protocol to clinical GMP requires extensive process changes, including use of stable producer cell lines, defined media, and potency tests Bridging preclinical development and clinical manufacturing.
Titer measurement variability is a known issue. The same stock can show different titers in different labs due to cell health, confluency, and incubation conditions. Validate your titer assay with a positive control vector.
Lentivirus can induce innate immune responses in some primary cells, leading to reduced expression. Pre treat cells with inhibitors of TLR pathways if needed.
Frequently Asked Questions
How long does the lentivirus protocol take from start to finish?
From seeding cells to having titered viral stock takes approximately 7 to 10 days. Transfection and harvest take 72 hours. Concentration and titering add 2 to 3 days. An additional week allows for stable cell line generation.
Can I use lentivirus for in vivo delivery?
Yes, but with caution. Lentivirus is often used for direct injection into brain or liver. The dose must be optimized and RCL testing performed. BSL 2+ containment is required. See guidelines from institutional biosafety committees.
What is the maximum insert size for a lentiviral transfer plasmid?
The transfer plasmid can accommodate up to 8 to 10 kilobases. Larger inserts reduce titer significantly. If your gene exceeds this limit, consider a dual vector system or use an alternative viral vector.
How do I ensure my lentivirus stock is free of wild type HIV?
The packaging plasmids lack envelope and accessory genes. The transfer plasmid contains deletions in the U3 region (SIN design). Production of RCL is extremely rare. Regular testing by p24 ELISA after serial passage is recommended for long term experiments.
References and Further Reading
- NCBI Bookshelf Free biomedical books covering lentivirus biology and vector design.
- EMBL EBI Training Training resources for molecular biology techniques, including viral vector production.
- Galaxy Training Network Open bioinformatics workflows for analyzing sequencing data from viral vectors.
- Bioconductor Software for genomic analysis, useful for integration site analysis.
- NCBI Sequence Read Archive Repository for raw sequencing data, including quality control of vector pools.
- Bridging preclinical development and clinical manufacturing J Transl Med, GMP platform for lentiviral vector production in CAR T cell therapy.
- Interleukin 38 promotes alveolar bone repair Stem Cell Res Ther, example of lentivirus use in stem cell research.
- Overexpression of Chimeric RNA by Retroviral Transduction Methods Mol Biol, practical protocols for gene delivery.
- Protocol for semi automatic quantitative bioimaging analysis of synapse loss STAR Protoc, linked protocol for assessing transduction effects.
- The mitochondrial protease LonP1 is a potential cardioprotective target J Transl Med, study using lentivirus for gene delivery in cardiac cells.